<SEC-DOCUMENT>0001659617-18-000016.txt : 20180215
<SEC-HEADER>0001659617-18-000016.hdr.sgml : 20180215
<ACCEPTANCE-DATETIME>20180215083056
ACCESSION NUMBER:		0001659617-18-000016
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180215
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180215
DATE AS OF CHANGE:		20180215

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Moleculin Biotech, Inc.
		CENTRAL INDEX KEY:			0001659617
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				474671999
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37758
		FILM NUMBER:		18616276

	BUSINESS ADDRESS:	
		STREET 1:		2575 WEST BELLFORT
		STREET 2:		SUITE 333
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77054
		BUSINESS PHONE:		713-300-5160

	MAIL ADDRESS:	
		STREET 1:		2575 WEST BELLFORT
		STREET 2:		SUITE 333
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77054
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-kq12018mda.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s1B9D5A578BAB5B8480F6D25DC5D1F315"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): February 15, 2018</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MOLECULIN BIOTECH, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact Name of Registrant as Specified in its Charter)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DELAWARE</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">001-37758</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">47-4671997</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or Other Jurisdiction of Incorporation or Organization)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File No.)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(I.R.S. Employer Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2575 WEST BELLFORT, SUITE 333, HOUSTON TX 77054</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices and zip code)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(713) 300-5160</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;(Registrant&#8217;s telephone number, including area code)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;(Former name or former address, if changed from last report)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">see </font><font style="font-family:inherit;font-size:10pt;">General Instruction A.2. below):</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;padding-bottom:32px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:432px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company [X]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]</font></div><div><br></div><hr style="page-break-after:always"><div><a name="sE2F8A9AB56AE5D4A8B9C1ED6FC338CE9"></a></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;-sec-extract:summary;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Item 8.01.&#160;&#160;&#160;&#160;Other Events.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"></font><font style="font-family:Calibri,sans-serif;font-size:12pt;">On February 15, 2018, Moleculin Biotech, Inc., (the "Company") issued a press release announcing that, pursuant to its continued collaboration with MD Anderson it has developed and licensed what it believes is a major breakthrough in immune-stimulating STAT3 inhibitors. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Item 9.01 &#160;&#160;&#160;&#160;Financial Statements and Exhibits.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">(d)&#160;&#160;&#160;&#160;Exhibits.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Exhibit No.&#160;&#160;&#160;&#160;Description</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:11pt;"><a style="text-decoration:underline;color:#0000FF;font-family:Calibri,sans-serif;font-size:11pt;-sec-extract:exhibit;" href="exh991-wp1066stat3.htm"><font style="font-family:Calibri,sans-serif;font-size:11pt;">99.1</font></a><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><a style="text-decoration:underline;color:#0000FF;font-family:Calibri,sans-serif;font-size:11pt;-sec-extract:exhibit;" href="exh991-wp1066stat3.htm"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Press release dated February 15, 2018</font></a></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;padding-left:192px;text-indent:-96px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;text-decoration:underline;">SIGNATURE</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;padding-bottom:48px;text-align:justify;padding-left:336px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">MOLECULIN BIOTECH, INC.</font></div><div style="line-height:120%;text-align:justify;padding-left:336px;text-indent:-336px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Date: February 15, 2018</font></div><div style="line-height:120%;text-align:justify;padding-left:336px;text-indent:48px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">By:&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:11pt;text-decoration:underline;">/s/ Jonathan Foster</font></div><div style="line-height:120%;text-align:justify;padding-left:336px;text-indent:48px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Jonathan Foster</font></div><div style="line-height:120%;text-align:justify;padding-left:336px;text-indent:48px;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Chief Financial Officer  </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:justify;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:10pt;">2</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sBD22F9FD1BCB518799B8507EF894932E"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;-sec-extract:summary;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;text-decoration:underline;">Exhibit No.</font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;text-decoration:underline;">Description</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:11pt;"><a style="text-decoration:underline;color:#0000FF;font-family:Calibri,sans-serif;font-size:11pt;-sec-extract:exhibit;" href="exh991-wp1066stat3.htm"><font style="font-family:Calibri,sans-serif;font-size:11pt;">99.1</font></a><font style="font-family:Calibri,sans-serif;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><a style="text-decoration:underline;color:#0000FF;font-family:Calibri,sans-serif;font-size:11pt;-sec-extract:exhibit;" href="exh991-wp1066stat3.htm"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Press release dated February 15, 2018</font></a></div><div><br></div><div><div style="line-height:120%;text-align:justify;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:10pt;">3</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh991-wp1066stat3.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s992B5434AA655003907BE3B57BF8FCEB"></a></div><div style="line-height:120%;text-align:left;"><img src="moleculinlogoa04.jpg" alt="moleculinlogoa04.jpg" style="height:44px;width:197px;"></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 99.1</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;">&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:Calibri,sans-serif;font-size:16pt;color:#2f5496;font-weight:bold;">Moleculin Announces Breakthrough Discovery of a New Molecule for Cancer Treatment</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:Calibri,sans-serif;font-size:16pt;color:#2f5496;font-weight:bold;">Cutting Edge Science Suggests New Molecule is Capable of Shutting Down Tumor Activity</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;">HOUSTON - February 15, 2018 - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center (&#8220;MD Anderson&#8221;), today announced that, pursuant to its continued collaboration with MD Anderson it has developed and licensed what it believes, based on preclinical testing, is a major breakthrough in its effort to develop a new cancer treatment that selectively kills highly resistant tumors.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;">&#8220;We believe our unique approach to develop immuno-stimulating STAT3 inhibitors just took a major step forward,&#8221; commented Walter Klemp, Chairman and CEO of Moleculin. &#8220;Our WP1066 portfolio has already resulted in multiple collaborations with some of the most prestigious cancer centers in the world and now this new discovery could dramatically improve our ability to treat a broader range of the most difficult cancers, and especially pancreatic cancer.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;">Dr. Don Picker, Moleculin&#8217;s Chief Science Officer, explained, &#8220;The scientific community recognizes the potential for small molecule immuno-stimulating STAT3 inhibitors to become a game-changer for treating cancer patients.  We believe this discovery may not only dramatically improve our ability to develop and deliver such therapies, it may also help support a new mechanistic understanding of oncogenic transcriptional activity.  Specifically, we now have preclinical evidence to suggest we are capable of controlling a process known as &#8216;ubiquitination&#8217; to block the activated form of STAT3, an important oncogenic transcription factor.  The study of the role of ubiquitination in cancer is cutting edge science and appears to hold great promise.  And, given the desperate lack of treatment options for indications like pancreatic cancer, we believe clinical researchers across the country have been eagerly awaiting a breakthrough like this.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;">&#8220;In developing our current lead STAT3 inhibitor, WP1066, for brain tumors, we have focused on its oral bioavailability and brain uptake,&#8221; continued Dr. Picker, &#8220;but at the same time we have continued our quest to expand this portfolio by the creating alternative inhibitors with increased bioavailability and altered tissue and organ distribution that are not affected by first-pass metabolism.  The lead molecule resulting from this new discovery is called WP1732 and it not only appears to share the same key mechanistic properties with WP1066, it has markedly different organ distribution and its dramatically increased solubility makes it ideal for administration via </font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;">standard IV injection.  Importantly, preclinical testing has also shown that WP1732&#8217;s properties make it a promising candidate for treating pancreatic cancer, one of the most resistant and deadly forms of cancer.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;">&#8220;So much has happened in the past few months, it&#8217;s important to recap where we are,&#8221; added Mr. Klemp.  &#8220;Moleculin has three potential breakthrough disruptive technologies - (1) Annamycin, an anticancer agent that is active against multidrug resistant tumor cells and has been designed to be non-cardio toxic (unlike currently approved drugs in this class), (2) immuno-stimulating STAT3 inhibitors like WP1066 and, now, WP1732, and (3) WP1122, a metabolic inhibitor that has been shown in preclinical testing to effectively block the energy supply required by cancer cells to function and proliferate.  Since our IPO in June 2016, we have accelerated to the point of having two drugs, Annamycin and WP1066, beginning clinical trials in the near term</font><font style="font-family:Times New Roman;font-size:12pt;">.&#8221; </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;">Mr. Klemp concluded, &#8220;We are now demonstrating the breadth of our drug pipeline and the benefits of collaborating with world-class cancer research centers. In the AML space, we expect patient dosing either in the United States or Poland to begin with Annamycin yet this quarter and we have begun to work with researchers at MD Anderson on using our immuno-stimulating STAT3 inhibitors to target AML as well.  A second clinical trial targeting brain tumors with WP1066 should begin dosing within the first half of the year.  In Poland, we are about to request a clinical trial authorization for WP1220 for the topical treatment of Cutaneous T-Cell Lymphoma (CTCL), which we expect will become our third clinical trial this year. WP1220 is our patented STAT3 inhibitor designed to be compatible with topical formulations and was selected based on its preclinical activity in CTCL cell lines and based on the need for better topical treatments for CTCL.  Additionally, we just announced positive data for WP1122, our glycolysis inhibitor, in a pancreatic cancer mouse model.  Along with the newly licensed discovery of WP1732, this sets the course for establishing the base for two more Investigational New Drug (IND) applications over the coming year and positions us as a leader in developing new approaches for pancreatic cancer. Our highly experienced leadership and expanding team is looking forward to sharing more progress on all of this activity as we move forward into 2018.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;font-weight:bold;">About Moleculin Biotech, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;">Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Our clinical stage drugs are Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, a modulator of hard-to-target tumor cell signaling mechanisms intended to attack tumor activity directly while also recruiting the patient's own immune system. We are also engaged in preclinical development of additional drug candidates, including compounds targeting the metabolism of tumors.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;">For more information about the Company, please visit </font><font style="font-family:Calibri,sans-serif;font-size:12pt;text-decoration:underline;">http://www.moleculin.com</font><font style="font-family:Calibri,sans-serif;font-size:12pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;font-weight:bold;">Forward-Looking Statements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;">Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of Annamycin, WP1066 and WP1220 to demonstrate safety and efficacy in clinical trials and the timing of the commencement of such trials, and the ability of WP1732 and WP1122 to achieve IND status and to demonstrate safety and efficacy in human patients.  These statements relate to future events, future expectations, plans and prospects. Although Moleculin Biotech believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin Biotech has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC.&#160; Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;font-weight:bold;">Contacts</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;">Joe Dorame, Robert Blum or Joe Diaz</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;">Lytham Partners, LLC</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;">602-889-9700</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;text-decoration:underline;">mbrx@lythampartners.com</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#160;</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>moleculinlogoa04.jpg
<TEXT>
begin 644 moleculinlogoa04.jpg
MB5!.1PT*&@H    -24A$4@   2@   !#" 8    O0Y@T    !'-"250(" @(
M? ADB     EP2%ES   +$@  "Q(!TMU^_    !QT15AT4V]F='=A<F4 061O
M8F4@1FER97=O<FMS($-3-NB\LHP    6=$58=$-R96%T:6]N(%1I;64 ,#$O
M,#,O,39:9]=.   @ $E$051XG.V==WP4U[7XOW=FMFK5*P($HG<,QF#< .,:
MMQ0GL9.7.$YB.R_=)7&2]TOR7EX<QRDNL9,X]<7.>TG<:V(;8XH--F# @*D"
M! C4NU;;9^;^_IA=:7>UDE8%@Y/]?CZ#/MR=N7/NE#/WGGO.N4)*R7N$#<@'
M+@$F 0[@/U+L=Q<0 JJ!54 [$'F/9,R0(<-IA#C)"BH/6 Y< <P'2H")0SC^
M*- $[ 3^#JP#.D91O@P9,IS&G P%Y02N :X%/CK:E0-/ $\"SP'!DU!_A@P9
M3A-&4T&-!ZX#O@!,'FSG^O:@;.D,$0P;A'4351&HBB#;;6/&N&R1QOD. P\#
M?P..CTCR#!DRG):,AH)R [< WP3&I-KA1+-?;JYN9T-5*[OKO!QN]M'L"Q,(
M&QB&!%." (3 IBEXG!ICLQU,&>/AS+&YG#.M@ OGEO2GM.J!GP"_ ?PC;4R&
M#!E.'T:JH"X&?@E,2_ZAN2,HG]E:S^-;:]ETI!V?-PQ2@BI 4T$1" $(2S<!
M2*Q=D!(,";II*2]586R1FPNG%_')L\=QZ8*R5,JJ"O@2\.I(&I0A0X;3A^$J
MJ"S@'N#+R3_L.]$E'UY]A+^^?8+FU@!H AP:FI+.J"TU4H)AF!#200AFC<_E
MYO,G\+4KIJ:J]"'@3L W[!-FR)#AM& X"FH*\!(P-;ZPH3TH[W[^ +]]_2A!
M7QA<-C1-&2TY>Y" $38@I#.A+)MO7S&-6RZ>E*RH#@*7 X=&78 ,&3*\9PQ5
M05T._ X8%U_XA[5'Y7>>VDM3LQ\\MA'UEH:"'C$@H'/NK!+N_^0\%DW)CS_Q
M"> F+&6:(4.&]R%#45 W82FG!*[]Q6;YU,8:<&EH-G54A4L'"1C^"#:;R@\_
M/(MO7CTM63NFE#M#A@RG/^DJJ)N!W\87;*OND-?_<@L':SM1LQT,U&?2S>A,
M7?+6'XI(V$34!6$@=$."+\Q'SJG@R:\M2=ZYC_P9,F0X_4E'05T(K(DO6+6S
M45[[T!:\@3":VV9U8Z+H9G3V+6)8Y:K X;21[[%3FF6G)-M!08Z=["P;^78-
MIRHPI:6+ H9)1\B@JSM,FS=,0W>()E^$=F^82# 2=4<08%,0FM)':4G Z JQ
M9$8Q+]RZE.(\1_P.?=J1(4.&TYO!%-1,8#4P-E;PPMOU\D,/;L(0H#E4:X9-
M-R%D !*GV\ZDDBP65N0Q?VPV<R?D,3'?R?3Q.<,V3.VMZ9)'VP/L.M+!SKHN
M=A[OXE!3-Y% Q%)8=A554ZQ>G #=&V;NA#Q>_>9YE!8X8^>M!2X"]@U7C@P9
M,KRW#*2@W, !+ ]Q -;O:9:7_&0C81'MR81T4!4F%&=QP;0B+II5Q-+)!4P=
MFY8G^(C8>[Q+;CK4QBM[F]EPL)6Z%C^8IN728%/0N\/,GY#/CKM7QLMR')A.
MQJ$S0X;W!0,IJ-]@>8@#L+_6*Q?_UUJ\'4&PJ8PKSN*J>65<>U;Y0%[>[QDO
M;6^03V^OXX5=C32V^$!5(&RP<F$YJ^\\-UZ^A'9ER)#A]*4_!74)5JJ3'BJ^
M]K(\7M_%RC/'<N.YX_GD>16G7"GUQR/KC\D_;:QAW8$6:/'S]>OG<=^_S8V7
MMT_[^F/'T4[YV*;C& *4--PG#--$2L'7+I[,^$+7L*_1^CW-\O&M=7C<VH 3
M$!#UP(^87#ZOE!5S3MW'XMZ7#LG:-C\VAYI@ET2 'C3XV#GC63PI_[1];MXO
M5#?[Y2]>/8Q#$PB1>#E-*7':-'[PH1D]/ZS=W21?VM6(L"F)SY* 4,A@7*Z3
MVZ_L,_M]6J"E*,L"_D#<T.ZFWVV7\\=F\_27%[-H:L%IV9!X;E@V0=RP; )O
M'6B5#ZTZS/TO'F#^^!SYF6438K+_ 9A!&M[FNXYU\.,G]D1#=-)P/#4E=(69
M7I3%31=5#KL-#_W]($^N/0P%[FC\SP!(P!\A2U-9,:=DV.<<*;]Z]3"'#[5"
MMB-19D5 >Y!)8SPLGI1_RN3[9Z&ZQ<\#C^\!IP)*TC-IF+BR[-RR8H(<FV=]
M(%_?V\)/']L-;AL)&DH WC"3QN;RL:7CY4@^J">+5 KJ"\0I)X OK9S$&9/R
M3COA!V/I]$*Q='HAMU\^53ZVN3;^I_' [<#/!ZO#85.P9=F): )534-!*0)#
M-UF_KWG8"JJFR2_7'&F#8@^J,ZDWD@()F(K >0K\T.+)<MO 8T?-LB<J*"$P
M(B;VDQ!9\*^(717@L8%#14U24(9AXG#;4>)Z5DZ;"AX[BMO6IP=E2'!EV=+Z
M]IX*DL7* KZ1O-/[43G%LW!*OKCGDW.2V_ -K/8.BHC[.^AF2G#;6'VPE<;.
MT+ "'3?L;Z&M-8#JT! RO?.>3ISN\OVST-]U[N]ZOQ_O2[*"^B)0=BH$.064
M8;5WU%$<&HVM/K8=:A_6\<^^TP"J0(A$_?:>)6?.D.$T(5Y!Y0%WG"I!3A%W
M8+5[V.B&[.,4KP@!NF3-WN8AU]?4$9(;#K>"0TO02!*K^YY14AF&BFY*B!@8
M$0,]:2-B)8Q\[Y8F&!KQ"NHJH/14"7***,5J]Y QL6R_D_)<9&D"PS3C?I7@
M4'FMJF7(];Z^OYG&5C^*K??6&!)48$:)!X^F8@P4)I0A0Q("B<T$1XI-,\ N
M3]_>>;R1_./ GT^5(*>08;7;-$Q0!2OGE+!Y?PN[ZCK!%54J$K"I5-5[V7JH
M32Z:DO[,YXL[&S%EXHV1ND&QV\%'%HWET0W'Z.P.@3/5_$:&#'WYV-+QS!F7
M@Z(J?>Q.(=VDP&UC;,'I-X,'O>]!(7#EJ13D%'(E5OM;AW*00! .&IPQ,9=P
MQ&173:*]21$"OR_,J[N;632E(.UZ-U2U6"X-\>@FDTO<7#BSB%^M/A03X/3]
M[&4XK9A2[A%3RCVG6HQA$5-0EP)_2>> AO:@/-[JYU!#-\<Z@AQO"M#2':0U
MJ!,P3 Q#X@OHY&19/A<Y-I5"IXW2/"?CBEU,R'4QM3R;N17#C\T[":3=_AX$
M$#;P.&U<-+N81]958YBR)X!9$6 *P;J#K7P[S2J?>;M>'F_V)?A;20!#LFA:
M(45Y3KQ!_?TQ_9(APR@04U#+Z.<%/5S?+3=4M?+FP3:V'N^DNME'AR\,$=.*
M?5.$%9<7B]051-_.V, V^M>4T9SD"MA5RK(=<DJIAR43<CE[2@'G3BUDS*ES
M%.NW_0,BP1O4N69>*3EN.UU&]'K$4 7[:CHYUNB7$TK=@[9MS;XFPD$#);O7
MGTE*4%6%:^:5T1W2H\;,C(;*\*^!!KA(6B;J[</M\KGM];R\NXEW:[L(^\+6
M.Z$IH"DH-A5A5X?UFEAK(D@:O"$:V@-LV-T(0I";X^#,B7GRBCFE7+F@C&GO
M0<!Q').QKD-@J ?Z0CKCBEQB1D6NW'*H!>*,VV@*#>U^WJQN8T*I>]"ZWMS7
M @HHJN@9OIFZP81B-Q?,*1:O[6\9M4'=YH-M<O.1#O8?[>!8JY_F0 0%D *R
M;2H5^2YF3LQGR:0\+IA9])YJQ+<.M<E-56WLJFZGILU/MVX"$DU5*,VR4UGB
M8?ZD?!97YC%C!,])55VW7+^_A6U5K1QHZJ8[8B"$P*4J5.2ZF#8QER63\KED
MWL#A0[MKNF1'()*8_D=@]:@1+)TVN WR>$M 'FWU]\E&*['L1#/&>!B3YQQV
M6]^J:I4DA<4@K+K'Y#B87MY['7<<Z9!=80-;W',(5GNR'1KS)^;V[%O=Z).O
M[6UFR[X6#K;Z\$5,!%#NL7/6U"(NG%/,TA%$GVA8SHK38P4O[VR4E]_]!B#!
MIH)=1639>E=; <SX&2LAK$Y4M/<TF"0"$$*@:+VA(Q+H#!NLV=W(FAWU?.<9
M!^=/+92?6CJ.3_>&IYQ,IF-=AR$K*#-Z35;.+&++_D2W D53B/C"K-O7PO5+
MQZ4ZO(?7]C3+/;5=EGM!C&C&B(MGEB2<:R0\_N8)^3_KC[+Q0 O>[C @H^$2
M275+P*S&X;%S5D6>O/[\"7SQDCZYWT>5EW<UR0=>.L2& \UT=P6C/?,4QC83
M$(+QA6ZN7CQ6?OFR*<PH]PQ)MML?W26?>NLXQUI\5O5*_'F$]:R_(<&AL7A\
MGKSN@@IN3;U(![<\LH-W]C6CNK6$*LR@CJ*HK/W>,IF4CKH/OUY]A/N?V8N:
ME12.8DB"72'N^<(B;KMDT.4F4_+J[D;Y\1]O)&)7^X2ZA-J#?.2<"OYZ^U(
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MCQQIK4)M5]$\]I[]%"%0LNSH 9UO_7D7,\ISY,7]Y">[X==;J>L*H>6ZK(]
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M?4O^??,)M!Q'_SM*RW"^>EL=7WYDIWSHAOFIY%B?HFQ$+)I:(*:/S9';CW2
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MQ!:+Z3E,RW:@%CA1<AVH!2ZT7*?EGV7V[J?K!GI'@%DE'IZ^=2FS4^0#ZG'
M[&]+8GYEGOC]38MP*PIZ9\B:=(SM:THKK"7?A9KO1,ESH!4ZT3R.WJJBG1L]
M9" [@GQH627_?5W_O;I'OW06BR85HK?Y+8_SV)ZF1'-JJ/DNJ_W9T7/$KI,
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#0F""

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
